P101 Polypeptides

Details P101 Polypeptides P101 Polypeptides

2000-04-28

2001-07-10

Slobodyansky, Elizabeth (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C530S350000

Reexamination Certificate

active

06258580

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to human p101, in particular human p101 polypeptides and human p101 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of disease states that involve leucocyte infiltration and activation, including inflammatory diseases such as COPD, ARDS, atherosclerosis, arthritis and psoriasis, etc., hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with human p101 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate human p101 activity or levels.


REFERENCES:
patent: 5856132 (1999-01-01), Stephens et al.
GenBank Accession No. AC002091, Hawkins et al., Genomic sequence from Human 17, complete sequence, Sep. 9, 1997.
Stephens, L.R., et al., “The G&bgr;&pgr; Sensitivity of a P13K Is Dependent upon a Tightly Associated adaptor, p101”, Cell, vol. 89, pp. 105-114, (1997).
Verma et al., “Gene therapy—promises, problems and prospects,” Nature, vol. 389, pp. 239-242 (1997).
Anderson et al., “Human gene therapy,” Nature, vol. 392, Supp. pp. 25-30 (1998).
Eck and Wilson, In Goodman and Gilmans the Pharmacological basis of therapeutics, McGraw Hill Publishers, pp. 77-101 (1995).
Crooke, Basic principles of Antisense Therapeutics, Springer-Verlag, eds., New York, pp. 1 and 4 (1998).
Branch, “A Good antisense molecule is hard to find,” TIBS 23, pp. 45-50 (1998).
Smith et al., “Nucleotide regulatory protein-mediated activation of phospholipase C in human polymorphonuclear leukocytes is dirupted by phorbol esters,” J. Bio. Chem., vol. 262(13), pp. 6121-6127 (1997).
Stephens et al., Cell, vol. 89, pp. 105-114 (1997).

Affiliated with

Also associated with

Rating

P101 Polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P101 Polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P101 Polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2520034